With Neil Woodford’s future uncertain, is this a good time to buy shares of Woodford Patient Capital Trust?

Would the departure of Woodford be a signal to buy? Studies show that the leaving of poor managers leads to a return to the performance of fund shares.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Following the recent debacle, coupled with poor performances, Woodford Patient Capital Trust (LSE: WPCT) shares have lost around 25% in the last three weeks alone.

Unlike Neil Woodford’s Equity Income fund, which was closed to new investments and withdrawals and lost 20% in value in June, his investment trust (Patient Capital) cannot have the same fate.

Closed-end funds are immune to withdrawals

Woodford Patient Capital Trust is a closed-end fund where funds are raised at inception with shares’ issuance as in an IPO. Like a company’s shares, closed-end funds trade on the stock market and Patient Capital is currently trading on the FTSE 350.

The valuation of closed-end funds is tangible and follows the value of their assets while the prices of their share is more volatile. Today, Patient Capital is trading at around 63p to £1, representing a 37% discount on its valuation.

The launch of Woodford’s personal fund in 2015 with great fanfare was a success, and attracted at its peak £15bn of investor money in 2017. The loss of confidence following poor performance and large investors withdrawals led to a decline in the fund’s shares.

Woodford is expected to leave, but what happens next?

Neil Woodford was a star manager at Invesco for 25 years, surpassing benchmark indices and surviving the dot.com bubble and the subprime crash.

Its recent poor performance and the subsequent closure of its equity income fund have forced Patient Capital’s board, in consultation with its broker Winterflood Securities, to consider Woodford’s departure. But what happens when a poor manager leaves a fund?

Depending on new hires and the reorganisation of the management team, Patient Capital – while keeping the same name – can be considered as a brand-new fund.

A revival for Patient Capital shares?

Usually, when star managers leave a fund, a massive withdrawal of investors follows, and the subsequent performance of the fund decreases. Famous examples include the departure of Richard Buxton from Schroders, which caused an exodus of £3.35bn.

But when poor performers leave the fund, the opposite also happens.

This chart (source: Adviser Investments) shows what happened to Vanguard Capital Opportunity Fund performance following a management change (indicated by the red dot) in 1998. Other empirical studies conducted by researchers at CASS Business School show that UK funds improve their performance after the departure of a poor manager by successfully reorganising the management team.

A good buy?

The current discount on the NAV makes an investment in Patient Capital a bargain, in my opinion. Bargain hunters could start buying at these levels and the planned changes at the head of the fund might make it more attractive to returning institutional investors.

Neil Woodford was a cheap manager because his fees were linked to his performance. On the downside, a new management could change the fee structure and make it fixed, but this could be easily compensated by the recovery in performance.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Jean-Philippe has no position in any company listed here. The Motley Fool UK has recommended Woodford Patient Capital. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

2 high-yield FTSE 250 shares I’d buy today — and 1 that I’d avoid

UK markets have felt some volatility after last week’s Budget and the FTSE 250 was no stranger to it. Our…

Read more »

Investing Articles

3 reasons the Rolls-Royce share price could soar over the next decade

Sustainable aviation fuel, narrow-body aircraft, and small nuclear reactors could all keep the Rolls-Royce share price climbing over the next…

Read more »

British flag, Big Ben, Houses of Parliament and British flag composition
Investing Articles

Here’s how much income I’d get if I invested my entire £20k ISA in cheap BT shares

BT shares are on the up but still cheap, while the FTSE 100 telecoms stock offers a good yield too.…

Read more »

Investing Articles

2 FTSE dividend shares yielding more than 6% with P/Es of less than 9!

Harvey Jones picks out two brilliant FTSE 100 dividend shares that yield more than 6% but are selling at strangely…

Read more »

Investing Articles

Up 105% in a year! Is this rocketing FTSE bank the perfect pick for my Stocks and Shares ISA?

Harvey Jones is drawing up a shortlist of stocks to purchase inside his Stocks and Shares ISA allowance. This FTSE…

Read more »

Investing Articles

Down 78%, is this once-hot AI growth stock set to explode like the Rolls-Royce share price?

Our writer asks if he should invest in Super Micro Computer (NASDAQ:SMCI) following the growth stock's massive recent decline.

Read more »

Investing Articles

Is it madness to buy Palantir shares after Q3 earnings?

Palantir stock's surging again after the firm's Q3 earnings report. But after a 150% gain, is it too late to…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

£6,000 in savings? Here’s how I’d aim to turn that into £1,032 a month of passive income!

A small investment in high-dividend-paying stocks with the returns used to buy more shares can generate big passive income over…

Read more »